Further Study Indicated for Follicular Lymphoma Vaccine

Genitope today announced that its independent Data Safety Monitoring Board (DSMB) reviewed the first planned interim analysis of data for efficacy in its pivotal Phase 3 clinical trial for treatment of follicular non-Hodgkin's Lymphoma (fNHL) and recommended that the trial continue as planned. People watching the study hoped that success and wrap-up of the trial would indicate moving forward with FDA approval.

The trial evaluates the safety and effectiveness of the MyVax(R) Personalized Immunotherapy in patients with previously untreated fNHL. The trial compares patients treated with MyVax(R) Personalized Immunotherapy to patients treated with a nonspecific immunotherapy control.

The next interim analysis of data for efficacy is now scheduled to occur in mid-2006.

LymphomaInfo Social